N30 Pharmaceuticals

N30 Pharmaceuticals, founded in 2007 and headquartered in Boulder, Colorado, is focused on developing a novel class of disease-modifying therapies aimed at preserving intracellular levels of GSNO (S-nitrosoglutathione), a key regulator of organ repair and regeneration. The company’s lead program targets cystic fibrosis, leveraging proprietary small molecule inhibitors of GSNOR to enhance GSNO levels and address inflammatory lung diseases.

With a commitment to advancing the field of cystic fibrosis treatment, N30 has successfully navigated the early phases of clinical trials, including proof-of-concept studies in asthma. Their innovative approach is supported by a robust portfolio of research and development activities that emphasize the therapeutic potential of GSNOR inhibitors in improving lung function and reducing inflammation in affected patients.

Generated from the website